Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > BUSINESS
BUSINESS
- Rystiggo Now Available for gMG Patients in Japan: UCB
November 29, 2023
- Amylyx Sets Up Japan Arm to Bring ALS Drug across Pacific
November 28, 2023
- UCB Japan Gathers Pace in Rare Disease Space with 2 New Launches for gMG
November 28, 2023
- Taisho to Go Private through MBO in a Pivot to Longer-Term Strategies
November 28, 2023
- Daiichi Sankyo Sued by Malaysia Hospital Group over TOB Interference
November 28, 2023
- Phesgo, Epkinly, Leqvio Hit Japan Market, Wegovy Launch Set for Feb. 22
November 24, 2023
- Sumitomo Wins Approval for Antibiotic Xenleta in China
November 24, 2023
- Otsuka’s UK Unit Astex to Receive Milestone Payment from AstraZeneca
November 24, 2023
- Lilly Restricts Shipments of Humalog, Lyumjev in Spillover from Novo’s Insulin Curb
November 22, 2023
- Alfresa Boosts Biz Alliance with Major Chinese Wholesaler
November 22, 2023
- BMS Japan Has Busy Years Ahead with String of Launches towards Doubling of Sales
November 22, 2023
- Daiichi Sankyo Wins ADC Patent Row against Seagen, Appeals Unfavorable Ruling in Enhertu Suit
November 21, 2023
- Janssen Files FGFR Inhibitor Erdafitinib for Urothelial Cancer in Japan
November 21, 2023
- Lagevrio Japan’s Top-Seller Drug in July-September, 2 Other COVID Meds Make Top 10: IQVIA
November 20, 2023
- Santen Snags European OK for Glaucoma/Ocular Hypertension Drug
November 20, 2023
- Xtandi Approved in US for Prostate Cancer in Earlier Setting
November 20, 2023
- Janssen Files Bispecific Antibody Amivantamab for NSCLC in Japan
November 20, 2023
- Takeda Files CMV Drug Maribavir in Japan
November 20, 2023
- Novo Nordisk to Quit Ozempic’s Single-Dose Devices, Focus on Multi-Dose Pen
November 17, 2023
- Astellas to Acquire US Upstart Propella for Prostate Cancer Drug
November 17, 2023
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…